Co-Inventors
Peeples, Mark (Nationwide Children's Hospital)
Applications
Research Materials
Diagnostics
Therapeutic Areas
Respiratory
Infectious Disease
Development Stages
Analytical Assay Performance Stage
The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.
Commercial Applications
This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus.
Competitive Advantages
This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors.
